Recruiting Erectile Dysfunction Studies in Beijing
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in ...
A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several...
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumor...
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation....
Study for AZD4360 in Participants With Advanced Solid Tumours
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic s...
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors....
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors...
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous ...
A Phase 2 in Adult Subjects With Hereditary Angioedema
A Phase 2 in Adult Subjects with Hereditary Angioedema...
About Erectile Dysfunction Clinical Trials in Beijing
Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.
There are currently 9 erectile dysfunction clinical trials recruiting participants in Beijing, BEIJING%20MUNICIPALITY. These studies are seeking a combined 1,154 participants. Research is being sponsored by Coherent Biopharma (Hefei) Co., Ltd., AstraZeneca, Merck Sharp & Dohme LLC and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Erectile Dysfunction Clinical Trials in Beijing — FAQ
Are there erectile dysfunction clinical trials in Beijing?
Yes, there are 9 erectile dysfunction clinical trials currently recruiting in Beijing, BEIJING%20MUNICIPALITY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Beijing?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Beijing research site will contact you about next steps.
Are clinical trials in Beijing free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Beijing studies also compensate for your time and travel.
What erectile dysfunction treatments are being tested?
The 9 active trials in Beijing are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.
Data updated March 2, 2026 from ClinicalTrials.gov